N-acetyl-D-mannosamine(N-acetyl-D-mannosamine) - 在研适应症：远端性肌病，局灶性节段性肾小球硬化症，遗传性包涵体肌病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

2-Actamido-2-deoxy-D-mannose、D-ManNAc、LB-301 - Leadiant Biosciences

+ [7]

靶点-

作用方式

刺激剂、调节剂

作用机制

糖基化刺激剂、蛋白调节剂

治疗领域

神经系统疾病遗传病与畸形皮肤和肌肉骨骼疾病+ [2]

在研适应症

远端性肌病局灶性节段性肾小球硬化症遗传性包涵体肌病

非在研适应症

慢性肾病塌陷性肾小球病肾病综合征

原研机构

National Institutes of Health

在研机构

National Human Genome Research Institute

National Institutes of Health

Leadiant Biosciences, Inc.

非在研机构

National Institute of Diabetes & Digestive & Kidney Diseases

权益机构

National Human Genome Research Institute

Leadiant Biosciences, Inc.

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C8H15NO6

InChIKeyMBLBDJOUHNCFQT-WCTZXXKLSA-N

CAS号3615-17-6

关联

9

项与 N-acetyl-D-mannosamine 相关的临床试验

NCT06664814

/ Recruiting临床2期IIT

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Background:
Focal segmental glomerulosclerosis (FSGS) is a disease that causes scarring in parts of the kidneys that filter waste. This can lead to protein loss in the urine, which can worsen kidney function. The kidneys may fail over time, and dialysis or a kidney transplant may be needed. Other treatments for this disease do not always work and often have adverse effects. Better treatments for FSGS are needed.
Objective:
To test a study drug (ManNAc) in people with FSGS.
Eligibility:
People aged 18 years and older with FSGS.
Design:
Participants will have 6 to 7 clinic visits over 14 weeks. Two of the visits will require overnight stays for 2 or 3 nights.
ManNAc is a white powder that comes in a sachet. It is dissolved in water and taken twice a day by mouth. Participants will take their first dose at the clinic. They will learn how to store ManNAc and prepare each dose. They will record their doses in a diary. They will also write down any adverse effects or troubles they have using the drug at home.
During clinic visits, participants will have physical exams with blood and urine tests. They will complete questionnaires about their health, sleep habits, and fatigue symptoms.
During overnight visits, participants will also have 24-hour urine collection.
A study team member will call participants 1 week after the first dose to check on their health. Follow-up phone calls will then be every 2 weeks after each clinic visit.
Participants may meet with a dietitian to discuss nutrition while taking the ManNAc.
Participants may choose to have genetic tests.

开始日期2025-06-29

申办/合作机构

National Human Genome Research Institute

ACTRN12623000609651

/ RecruitingN/AIIT

An open-label, randomised, three-arm crossover study to examine the comparative pharmacokinetics of ManNAc administered as an oral solution and as two novel oral tablet formulations in healthy adult males

开始日期2023-07-13

申办/合作机构

University of South Australia

ACTRN12622000394741

/ CompletedN/AIIT

An open-label, randomised, two-arm crossover study to determine the absolute oral bioavailability of ManNAc in healthy adult males

开始日期2022-11-17

申办/合作机构

University of South Australia

100 项与 N-acetyl-D-mannosamine 相关的临床结果

登录后查看更多信息

100 项与 N-acetyl-D-mannosamine 相关的转化医学

登录后查看更多信息

100 项与 N-acetyl-D-mannosamine 相关的专利（医药）

登录后查看更多信息

1,370

项与 N-acetyl-D-mannosamine 相关的文献（医药）

2025-08-01·FOOD CHEMISTRY

Metabolomics unravels the formation pathway of advanced glycation end products in preserved egg yolk mediated by OH− during pickling

Article

作者: Xiang, Xiaole ; Dong, Shiqin ; Li, Shugang ; Huang, Yiqun ; Ye, Lin ; Yu, Zhuosi ; Chen, Le ; He, Yu

Metabolomics was first applied to explore the formation pathway and regulatory factors for advanced glycation end products (AGEs) in preserved egg yolk (PEY) during pickling. Most reactions that contributed to formation of AGEs, including oxidation and/or degradation of matrix/precursors and Maillard reaction, occurred primarily in PEY in early stage, and lipid oxidation occurred prior to protein oxidation. Additionally, the formation of N^ε-carboxymethyl-lysine (CML) in PEY was mainly attributed to glyoxal derived from D-glucuronic acid in early stage based on the correlation between metabolites and AGEs. Reactive oxygen radicals from oxidized lipids also promoted the enrichment of CML and N^ε-carboxymethyl-lysine (CEL). Moreover, during later stage, the accumulation of CEL was enhanced through methylglyoxal from Schiff bases, and acidic compounds could inhibit AGEs via hindering Maillard reaction. This manuscript pioneered the application of metabolomics to reveal the formation pathway of AGEs, and will provide new perspective on AGEs formation in foods.

2025-06-01·FOOD CHEMISTRY

Proteomics and metabolomics elucidate the biosynthetic pathway of acid stress-induced exopolysaccharides and its impact on growth phenotypes in Lactiplantibacillus plantarum HMX2

Article

作者: Wang, Yanbo ; Zeng, Hong ; Wang, Bei ; Yang, Zhijie ; Yang, Xinyu

Lactiplantibacillus plantarum has been well acknowledged to produce exopolysaccharides (EPS) as a defense mechanism against acid stress. However, the complete biosynthetic pathway of EPS in L. plantarum and its impact on the cell growth and primary metabolism were still unclear. To fill these gaps, we carried out phenotypic, proteomic and metabolomics analysis of L. plantarum HMX2 cultured under different acidic conditions. Component and structure analysis showed that the repeating unit of EPS consisted of N-acetylmannosamine, N-acetylglucosamine, galactose, mannoses and glucoses. Multiomics analysis facilitated the curation and entablement of the complete EPS biosynthetic pathway ready for use in genome-scale metabolic models. Furthermore, proteomics and metabolomics data indicated that compared to the pH 6.5 condition, the acid stress at pH 4.5 significantly accelerated glycolysis and EPS biosynthesis processes while reduced the metabolic fluxes through the TCA cycle and the lactic acid fermentation, which suggested a trade-off between primary and secondary metabolism.

2025-06-01·PROCESS BIOCHEMISTRY

Improving 3′-sialyllactose biosynthesis in Escherichia coli by engineering Neisseria meningitidis 406Y α2,3-sialyltransferase

作者: Lin, Qian ; Wang, Hao ; Zhang, Wenbo ; Huang, Zhaolin ; Wang, Ruiyan ; Sheng, Mian ; Zhu, Yingying ; Liu, Yuanlin ; Mu, Wanmeng

3′ -Sialyllactose (3′ -SL, Neu5Acα2,3 Galβ1,4Glc), a prominent sialylated human milk oligosaccharide (HMO), has attracted significant attention due to its diverse physiol. properties.The efficient α2,3-sialyltransferase (α2,3-SiaT) is crucial for the biosynthesis of 3 ′ -SL.In this study, the 3 ′ -SL biosynthetic pathway was constructed in EZAK (E. coli BL21(DE3) ΔlacZΔnanAΔnanK). 406NST, which exhibits a high 3 ′ -SL yield and low byproduct formation, was chosen for mol. modification.Five amino acid differences between 406NST and NST were targeted for site-directed mutagenesis.Subsequently, saturation mutagenesis was carried out at the D40 position, followed by superimposed multipoint mutagenesis to generate the optimal strain Z28 (406NST-D40R-N113D-P120H), resulting in an extracellular 3 ′-SL yield of 4.67 g/L in shake flasks.In a 5 L bioreactor, the extracellular 3 ′-SL yield reached 29.54 g/L, achieving an overall 3 ′-SL yield of 0.52 g/L/h and a lactose conversion yield of 0.62 mol 3 ′-SL/mol.In conclusion, a highly active and specific α2,3-SiaT was successfully constructed, significantly improving the yield of 3 ′ -SL.

100 项与 N-acetyl-D-mannosamine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12536

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
远端性肌病	临床3期	-	National Institutes of Health	-
远端性肌病	临床3期	-	Leadiant Biosciences, Inc.	-
局灶性节段性肾小球硬化症	临床2期	美国	National Human Genome Research Institute	2025-06-29
遗传性包涵体肌病	临床2期	美国	National Human Genome Research Institute	2015-02-05
慢性肾病	临床1期	美国	National Institute of Diabetes & Digestive & Kidney Diseases	2016-07-07
塌陷性肾小球病	临床1期	美国	National Institute of Diabetes & Digestive & Kidney Diseases	2016-07-07
肾病综合征	临床1期	美国	National Institute of Diabetes & Digestive & Kidney Diseases	2016-07-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02346461 (Pubmed \| Genet Med) 人工标引	临床2期	遗传性包涵体肌病	12	ManNAc	選蓋醖鹽餘糧網鏇築鑰(築窪築鏇鹽餘淵壓繭網) = 網鏇鹹構衊齋築鬱鏇壓窪選鹽製淵憲鏇鹽構繭 (選顧齋鬱網醖選製齋鹽 )	积极	2021-11-01
NCT02639260 (Phase 1 Study of N-Acetylmannosamine (ManNAc) for Glomerular Disease, ASN2020)	临床1期	肾小球疾病	7	ManNAc 3g single dose	膚齋憲製襯膚鏇憲鑰鏇(襯觸鬱構夢鏇網鬱鏇獵) = There were no serious adverse events. Most subjects (5 of 6) that received ManNAc twice daily showed a marked reduction in urine PCR (26-54%), which correlated with the degree of glomerular hyposialylation 積艱糧衊鏇築遞壓觸醖 (夢選積積壓獵鹹窪願選 ) 更多	积极	2020-10-19
NCT02346461 (CTgov)	临床2期	遗传性包涵体肌病	12	ManNAc (ManNAc: Cohort A)	顧鑰鏇鹹構網夢願繭鹽(積夢襯鹹艱遞簾遞簾鹽) = 夢簾膚簾鏇範鏇窪願膚夢夢繭壓構構遞遞鬱遞 (齋鏇積蓋觸範築鹹艱糧, 1776) 更多	-	2019-04-16
NCT02346461 (CTgov)	临床2期	遗传性包涵体肌病	12	ManNAc (ManNAc: Cohort B)	顧鑰鏇鹹構網夢願繭鹽(積夢襯鹹艱遞簾遞簾鹽) = 膚遞壓憲蓋壓觸獵憲糧夢夢繭壓構構遞遞鬱遞 (齋鏇積蓋觸範築鹹艱糧, 2710) 更多	-	2019-04-16
ASN2010	N/A	微小病变性肾病 Angptl4 \| NPHS2-Angptl4 \| PAN	-	ManNAc	夢構積夢廠願醖顧獵壓(醖遞築鹽餘網膚選鬱顧) = 鹹鏇範鏇淵鏇觸窪鬱齋廠構獵壓製膚製鹽願構 (蓋繭鏇廠艱鏇齋顧夢簾 )	积极	2010-11-16